



(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/725 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/065157

(22) International Filing Date:

23 December 2021 (23.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/133,171	31 December 2020 (31.12.2020)	US
63/136,172	11 January 2021 (11.01.2021)	US
63/175,003	14 April 2021 (14.04.2021)	US
63/255,795	14 October 2021 (14.10.2021)	US
63/288,477	10 December 2021 (10.12.2021)	US

(71) Applicant: **SANA BIOTECHNOLOGY, INC.** [US/US];
188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(72) Inventor; and

(71) Applicant: **FRY, Terry, J.**; c/o Sana Biotechnology, Inc.,
188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(72) Inventors: **SCHREPFER, Sonja**; 1 Tower Place, Suite
500, South San Francisco, CA 94080 (US). **WENG, Lin-
dong**; c/o Sana Biotechnology, Inc., 188 East Blaine Street,
Suite 400, Seattle, WA 98102 (US).

(74) Agent: **MACDOUGALL, Christina, A.** et al.; Morgan,
Lewis & Bockius LLP, One Market, Spear Street Tower,
San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY




FIG. 1

(57) **Abstract:** Disclosed herein are engineered cells and/or hypoinmunogenic cells including engineered and/or hypoinmunogenic stem cells, engineered and/or hypoinmunogenic cells differentiated therefrom, engineered and/or hypoinmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoinmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoinmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

[Continued on next page]

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*